Chartwell Investment Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Chartwell Investment Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$717K	Buy	18,213 +144	+0.8%	+$5.81K	0.02%	377
2024 Q2	$705K	Sell	18,069 -2,951	-14%	-$118K	0.02%	374
2024 Q1	$905K	Buy	21,020 +500	+2%	+$23K	0.03%	373
2023 Q4	$945K	Sell	20,520 -2,781	-12%	-$98.3K	0.03%	365
2023 Q3	$796K	Hold	23,301	–	–	0.03%	367
2023 Q2	$897K	Buy	23,301 +1,133	+5%	+$45K	0.03%	359
2023 Q1	$793K	Sell	22,168 -1,462	-6%	-$54K	0.03%	362
2022 Q4	$932K	Buy	23,630 +1,341	+6%	+$48.8K	0.04%	347
2022 Q3	$805K	Buy	22,289 +781	+4%	+$28.1K	0.03%	361
2022 Q2	$654K	Buy	+21,508	New	+$650K	0.03%	383

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Chartwell Investment Partners's XENE Position: Q3 2024 in Review

Chartwell Investment Partners increased its Xenon Pharmaceuticals (XENE) stake by 0.8% in Q3 2024, buying an estimated $5.81K and bringing the position to 18,213 shares worth $717K. The position accounts for 0.02% of the portfolio, ranked #377.

Chartwell Investment Partners first reported a position in XENE in Q2 2022 and has held it in 10 quarters since. The position peaked at $945K in Q4 2023. 203 funds tracked by Wall St. Rank hold XENE as of Q3 2024.

Chartwell Investment Partners held 18,213 shares of Xenon Pharmaceuticals worth $717K as of Q3 2024.
Chartwell Investment Partners bought 144 Xenon Pharmaceuticals shares in Q3 2024, an estimated $5.81K.
Xenon Pharmaceuticals made up 0.02% of Chartwell Investment Partners's portfolio in Q3 2024, its #377 holding.
Chartwell Investment Partners first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
Chartwell Investment Partners's Xenon Pharmaceuticals position peaked at $945K in Q4 2023.
203 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.